✦ LIBER ✦

A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS

✍ Scribed by Carr, R.D.; Gantz, I.; Erondu, N.; Moreno, M.; Suryawanshi, S.; Musser, B.; Nayee, J.; Johnson-Levonas, A.O.; Heymsfield, S.; Amatruda, J.

Book ID: 118635887
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 144 KB
Volume: 9
Category: Article
ISSN: 1567-5688
DOI: 10.1016/s1567-5688(08)70044-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A one-year study to assess the safety an

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

✍ M. S. Kipnes; P. Hollander; K. Fujioka; I. Gantz; T. Seck; N. Erondu; Y. Shentu; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

A clinical trial assessing the safety an

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

✍ Proietto, J; Rissanen, A; Harp, J B; Erondu, N; Yu, Q; Suryawanshi, S; Jones, M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 494 KB

A clinical trial assessing the safety an

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

✍ Aronne, L J; Tonstad, S; Moreno, M; Gantz, I; Erondu, N; Suryawanshi, S; Molony, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 711 KB

A 52-week open-label study of the safety

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

✍ Gopal, S.; Vijapurkar, U.; Lim, P.; Morozova, M.; Eerdekens, M.; Hough, D. 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 288 KB

COMPARE - Results of a randomised study

COMPARE - Results of a randomised study to assess the renal safety and efficacy of ibandronate and zoledronate in multiple myeloma patients

✍ Raoul Bergner; Hartmut Goldschmidt; Martin Kropff; Wolfram Pönisch; Claudia Kiew 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 69 KB

P01-317 - Safety and tolerability of ari

P01-317 - Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric patients: Results from a 52-week open-label study

✍ W. Landsberg; J.-Y. Loze; G. Lau; G. Manos; R. McQuade; L. Kamen; R. Marcus; R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 French ⚖ 31 KB